Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

VaxGen Awarded $80.3M For Anthrax Vaccine Development

Oct. 2, 2003

By Aaron Lorenzo

VaxGen Awarded $80.3M For Anthrax Vaccine Development

Oct. 2, 2003

By Aaron Lorenzo

Pushing Its CNS Programs, Acorda Files For $75M IPO

Oct. 1, 2003

By Aaron Lorenzo

Inex Begins Rolling NDA For Onco TCS In Non-Hodgkin's

Oct. 1, 2003

By Aaron Lorenzo

Inex Begins Rolling NDA For Onco TCS In Non-Hodgkin's

Oct. 1, 2003

By Aaron Lorenzo

Pushing Its CNS Programs, Acorda Files For $75M IPO

Oct. 1, 2003

By Aaron Lorenzo

NIH Disperses Nearly $90M For HIV Vaccines, Other Diseases

Sep. 30, 2003

By Aaron Lorenzo

NIH Disperses Nearly $90M For HIV Vaccines, Other Diseases

Sep. 30, 2003

By Aaron Lorenzo

Angiotech Garners $218.8M With Follow-On Public Stock Offering

Sep. 29, 2003

By Aaron Lorenzo

Angiotech Garners $218.8M With Follow-On Public Stock Offering

Sep. 29, 2003

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.